Sunshine plans an aggressive clinic opening schedule in rural and suburban areas along with franchising. Sunshine Care Virtual Clinics and SunshineCare.Online are companies created from the result of prior ObamaCare In…
Day: October 24, 2022
With $2M in Pre-Seed Funding, HeyRitual Launches to Take Couples Therapy Into the Digital Age
Ritual combines 1:1 guidance from experienced relationship experts with scientifically validated tools in a user-friendly platform
Logo HeyRitual…
WHILL Power Chairs Announces Partnership With Stealth Products
Power chair experts team up to assist mobility-impaired consumers with a broader range of medical conditions
WHILL model F and C2 with Stealth Acce…
The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
Virtual workshop on Nov. 17-18 bridges the gap between critical stakeholders to pinpoint today’s challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
Be the Match
Be the Match
MINNEAPOLIS – October 24, 2022 – (Newswire.com)
The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International Blood and Marrow Transplant Research® (CIBMTR®), and the National Marrow Donor Program® (NMDP)/Be The Match®, brings key stakeholders together to identify ongoing needs and opportunities in cell and gene therapy for advocacy, measurement of value and impact and sustainability. The virtual workshop on Nov. 17-18, 2022, joins providers, payers, government agencies and industry members who will work together to define essential factors needed to create a sustainable cell and gene therapy ecosystem.
“NMDP/Be The Match is proud to be one of the sponsors of this important forum that has interests for all key stakeholders across the ecosystem,” said Jeffery Auletta, M.D., Senior Vice President, Patient Outcomes and Experience, of NMDP/Be The Match, Chief Scientific Director, CIBMTR. “Our established relationships with a global network of transplant centers and cell and gene therapy developers uniquely position NMDP/Be The Match to bring these experts together to identify the needs and opportunities in this field for advocacy, measurement, and sustainability.”
Dr. Auletta will join industry and transplant center partners and other professionals to address the question, “Are Center-Specific Outcomes Possible for CAR T-cell Immunotherapy?” The participants will focus on the perspectives of the payer, data acquisition and analysis, and center perspectives in defining outcomes for CAR T cells. They will also discuss healthcare inequity, specifically barriers to access and their impact on cell therapy outcomes. The speakers will incorporate the evolving cell therapy landscape from industry collaboration to clinical trials and real-world treatment in their presentations and in a moderator-led roundtable with attendee participation. Visit the event website to register and see the complete schedule and list of presenters.
In addition to NMDP/Be The Match, the event co-hosts include:
The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. For more information about ASTCT, visit www.astct.org and follow us on Twitter, @ASTCT.
The CIBMTR, a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin, facilitates critical cellular therapy research through a clinical database of more than 600,000 patients from more than 350 centers worldwide, with a biospecimen repository of more than 195,000 samples.
Background:
The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®—a collaboration with the Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.
Contact Information:
Phyllis Grabot
[email protected]
Bonnie Quintanilla
[email protected]
Press Release Service
by
Newswire.com
Original Source:
The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US
Test offers EoE patients a simple, clinically proven method to control their disease. “…Beyond thrilled to use this at Phoenix Children’s Hospital…” – Dr. Schroeder, Medical Director, Eosinophilic Disease Clinic, Phoenix Children’s Hospital
AURORA, Colo. – October 24, 2022 – (Newswire.com)
Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children’s Hospital of Colorado, performed the Esophageal String Test® (EST) on a patient in early September. The test will be offered regularly at the hospital.
The EST was also performed on patients in the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital.
“I am now beyond thrilled to use this new esophageal surveillance technique at Phoenix Children’s and for my patients with eosinophilic gastrointestinal disorders. The EST is a game-changer for my patients who are looking for a less invasive and less expensive way to screen their disease activity,” said Dr. Shauna Schroeder, Medical Director for the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. She further stated “Having trained in Denver, I had experience using the EST as a research tool in patients with eosinophilic esophagitis. I am now able to more granularly adjust medications and diets improving the care of my patients with eosinophilic esophagitis.”
The Esophageal String Test® utilizes a simple collection device, the EnteroTracker®, to collect upper gastrointestinal samples from adults and children. The samples are sent to an independent reference lab for analysis of disease activity. Several other clinics around the country are planning to offer the test soon.
About EnteroTrack
EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.
Contact Information:
Robin Shandas
CEO, Media and Investor Inquiries
[email protected]
Brookelynn Stillwell
General Inquiries
[email protected]
Press Release Service
by
Newswire.com
Original Source:
Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
LAS VEGAS – October 24, 2022 – (Newswire.com)
Gb Sciences, Inc. (“GbS”; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS’ proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS’ proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company’s first non-cannabis formulations to advance in preclinical studies.
“We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations,” said Dr. Andrea Small-Howard, Gb Sciences’ President and Chief Science Officer. “This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs.”
For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.
The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Media Contact
Alexis Quintal
Contact Information:
Madeleine Moench
[email protected]
Press Release Service
by
Newswire.com
Original Source:
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates
…